High-Risk Patients with Differentiated Thyroid Cancer T4 Primary Tumors Achieve Remnant Ablation Equally Well Using rhTSH or Thyroid Hormone Withdrawal

Bartenstein, Peter; Calabuig, Elisa Caballero; Maini, C.L.; Mazzarotto, Renzo; Fuentes, M.A. Muros de; Petrich, Thorsten; Rodrigues, Fernando; Casas, J.A. Vallejo; Vianello, Federica; Basso, Michela; Balaguer, Marcelino Gómez; Haug, Alexander; Monari, Fabio; Vaño, R. Sánchez; Sciuto, Rosa; Magner, James A.

doi:10.1089/thy.2013.0157

Cited by 28 publications

(23 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our ablation success rates in the high‐risk patients are somewhat lower than those reported in smaller studies by Bartenstein et al . ( n = 144) and Pitoia et al .…”

Section: Discussioncontrasting

confidence: 85%

Patients with high‐risk differentiated thyroid cancer have a lower I‐131 ablation success rate than low‐risk ones in spite of a high ablation activity

Winter

Krohn

et al. 2016

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

“…Our ablation success rates in the high‐risk patients are somewhat lower than those reported in smaller studies by Bartenstein et al . ( n = 144) and Pitoia et al .…”

Section: Discussioncontrasting

confidence: 85%

Patients with high‐risk differentiated thyroid cancer have a lower I‐131 ablation success rate than low‐risk ones in spite of a high ablation activity

Winter

Krohn

et al. 2016

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

“…Therefore, it is recommended that rhTSH be applied routinely for RIT to improve patient QOL. Furthermore, diagnostic monitoring is feasible using rhTSH as compared with that using thyroid hormone withdrawal because of not only the efficacy of rhTSH but also its effect on improving the QOL [21,22]. The radioactive iodine dose was different in each patient.…”

Section: Discussionmentioning

confidence: 99%

Does 131I Radioactivity Interfere with Thyroglobulin Measurement in Patients Undergoing Radioactive Iodine Therapy with Recombinant Human TSH?

Bang

Lee

Kim

2015

Nucl Med Mol Imaging

View full text Add to dashboard Cite

Objectives Recombinant human thyroid-stimulating hormone (rhTSH) is widely used in radioactive iodine therapy (RIT) to avoid side effects caused by hypothyroidism during the therapy. Owing to RIT with rhTSH, serum thyroglobulin (Tg) is measured with high 131 I concentrations. It is of concern that the relatively high energy of 131 I could interfere with Tg measurement using the immunoradiometric assay (IRMA). We investigated the effect of 131 I administration on Tg measurement with IRMA after RIT. Methods A total of 67 patients with thyroid cancer were analysed retrospectively. All patients had undergone rhTSH stimulation for RIT. The patients' sera were sampled 2 days after 131 I administration and divided into two portions: for Tg measurements on days 2 and 32 after 131 I administration. The count per minute (CPM) of whole serum (200 μl) was also measured at each time point. Student's paired t-test and Pearson's correlation analyses were performed for statistical analysis. Results Serum Tg levels were significantly concordant between days 2 and 32, irrespective of the serum CPM. Subgroup analysis was performed by classification based on the 131 I dose. No difference was noted between the results of the two groups.Conclusions IRMA using 125 I did not show interference from 131

show abstract

“…Perhaps because of the medicolegal implications, the ATA guidelines, in spite of all the available evidence with regard to equal efficacy and superior patient quality-of-life compared to levothyroxine withdrawal [23][24][25][26][27][28][29][30][31][32] I ablation. In Recommendation 54A of the ATA guidelines it is in contrast stated that Bpreparation with rhTSH stimulation is an acceptable alternative to thyroid hormone withdrawal^in patients with low-risk DTC according to ATA guidelines.…”

mentioning

confidence: 99%

Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer

Verburg

Aktolun²,

Chiti

et al. 2016

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Recently the American Thyroid Association (ATA) released the third version of one of the most cited differentiated thyroid cancer (DTC) guidelines under the title B2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer^ [1]. Compared to the earlier versions [2,3], these guidelines are a major departure, as the volume of the text, the number of recommendations and the number of references have increased considerably.We fully understand the effort involving many hours of work that must have been required for the rigorous screening of the literature to produce the evidence tables and the eventual definitions of the recommendations. The document consists of roughly 73,000 words which make up the 101 recommendations and the explanatory text and comments. In the current ATA guidelines, most of the text appears eminently sensible and represents a significant advance from previous DTC-related guidelines published by the ATA as well as other societies, including the 2008 European Association of Nuclear Medicine (EANM) guidelines on 131 I therapy of DTC [4][5][6][7]. For instance, we welcome the clear division of indications for initial 131 I treatment of DTC patients after total thyroidectomy into ablation, adjuvant therapy and therapy. Furthermore, this change in terminology which we strongly support much more clearly delineates the role of 131 I in the care of patients with DTC in other disciplines, especially medical oncology. Considering all the factors that have to be weighed in formulating recommendations this is a huge dedicated effort that has come to fruition.

show abstract

High-Risk Patients with Differentiated Thyroid Cancer T4 Primary Tumors Achieve Remnant Ablation Equally Well Using rhTSH or Thyroid Hormone Withdrawal

Abstract: Use of rhTSH as preparation for thyroid remnant ablation in patients with T4 primary tumors achieved a rate of ablation success that was high and noninferior to the rate seen after THW, and rhTSH was well tolerated.

Cited by 28 publications

References 13 publications

Patients with high‐risk differentiated thyroid cancer have a lower I‐131 ablation success rate than low‐risk ones in spite of a high ablation activity

Patients with high‐risk differentiated thyroid cancer have a lower I‐131 ablation success rate than low‐risk ones in spite of a high ablation activity

Does 131I Radioactivity Interfere with Thyroglobulin Measurement in Patients Undergoing Radioactive Iodine Therapy with Recombinant Human TSH?

Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer

Contact Info

Product

Resources

About